Skye Bioscience, Inc. SKYE
1.67
(0.03)
(1.76%)
as of 25 Sep
- Market cap
- $7.5M
- P/E
- 0.0×
Follow SKYE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(94.31%) | (126.85%) | (167.97%) | (233.87%) | |
| (83.39%) | (110.66%) | (136.16%) | (159.80%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(157.19%) | (282.63%) | (642.85%) | 9,362.64% | |
Free Cash Flow per Share |
(8.31) | (8.61) | (8.56) | (7.71) | |
Free Cash Flow |
(41.20) | (42.71) | (42.43) | (38.27) | |
Capital Expenditures |
0.26 | 0.35 | — | 0.54 | |
| Other line items | |||||
Cash ROIC |
(60.85%) | (94.10%) | (162.46%) | (405.68%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.77 | 0.74 | 0.77 | |
Depreciation/Fixed assets |
0.69 | 0.80 | 0.95 | 20.96 | |
Capex/Depreciation |
0.37 | 0.49 | 0.00 | 0.78 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(8.36) | (8.69) | (8.56) | (7.82) | |
Capex per Share |
0.05 | 0.07 | 0.00 | 0.11 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates